SlideShare uma empresa Scribd logo
1 de 11
Clinical Cases for CCF

   Prof. Dr. Talat Ahmed
Case Scenario for Clinical pharmacokinetics
• A 64 yrs old male had heart failure was put on digoxin therapy in tablet
  form, formulated by XY pharmaceutical. Initially he was given 0.5 mg 8
  hourly for three days followed by 0.125 mg/day. Simultaneously he was
  suffering from severe cough, fever and malaise, the physician after
  thorough investigations diagnosed as a case of lower respiratory tract
  infection and prescribed 100mg/d doxycycline initially for one week
  which was further extended to 10 days. The patient suffered from
  diarrhea, doxycycline was discontinued, a course of metronidazole was
  given and patient got cured.
• After few days patient complaint of fatigue, palpitations and dyspnea.
  The dose of digoxin was increased to 0.25mg/ day and he felt better.
• After several years he was diagnosed for chronic renal failure, blood urea
  and creatinine is raised. He developed heart sinking and palpitation. ECG
  showed pulses bigeminy. Serum digoxin was 2.8ng/ml. Digoxin therapy
  was stopped for three days. KCl was administered for few days The
  plasma level was now 1ng/ml and the dose of digoxin was adjusted to
  0.125mg digoxin/day.
Case Scenario for Clinical pharmacokinetics
1. What is form?
2. Why patient was asked to take the digoxin
   formulated by XY pharmaceutical only?
3. Why he suffered from diarrhea?
4. Why he was given high doses of digoxin initially?
5. Why the patient complaint of fatigue, palpitations
   and dyspnea.
6. Why the physician had to increase the dose of
   digoxin?
7. Therapeutic blood monitoring is required, at which time
   you will take blood sample?
8. Plasma concentration is found to be 0.35 ng/ml.
   How will you calculate the new dose?
8. What is the first symptom of digoxin toxicity leading
    to diagnosis?
9. Why patient developed cardiac toxicity?
10. Enumerate the formulas applied for Estimation of
    GFR & Creatinin clearance
11.What is the normal range of serum digoxin level?
12. After increasing the dose to 0.25 mg/day how long
    it took to improve the patients condition and was
    stabilized?
13. What is the mechanism of development of pulses
    bigeminy?
14. What will be effect of chronic renal failure on
    plasma half life of digoxin?
15. Later, on reducing the dose from 0.25 to 0.125 mg,
    how long will it take to reach Css?
Clinical Evidences
Doxycycline
• Antibiotics might increase digoxin absorption
  by inactivating intestinal bacteria
• John R Horn, Pharmacy times 2004
Azole Derivatives
• Antifungal Agents (Azole Derivatives,
  Systemic): May increase the serum
  concentration of Cardiac Glycosides.
  (UpToDate)
Doxycycline
• Unlike many tetracyclines, doxycycline does
  not appear to accumulate in patients with
  impaired renal function, and aggravation of
  impairment may be less likely. Similarly, there
  is also no evidence that doxycycline causes
  severe hepatitis (BMJ)
Metronidazole
• DOSING: RENAL IMPAIRMENT
• To reduce possible accumulation in patients receiving
  multiple doses, consider reduction to 50% of dose or
  every 12 hours; Note: Dosage reduction is unnecessary in
  short courses of therapy. Some references do not
  recommend reduction at any level of renal impairment
  (Lamp, 1999).

• DOSING: HEPATIC IMPAIRMENT — Unchanged in mild
  liver disease; reduce dosage in severe liver disease.
4-variable MDRD," (Modification of Diet in Renal
Disease Study Group) serum creatinine, age
  race, & Gender.
CKD-EPI including urinary albumin
NSR=normal sinus rhythem
PVB= premature ventricular beat
Therapeutic Dose   Toxic dose
Thank you

Mais conteúdo relacionado

Mais procurados

CONGESTIVE CARDIAC FAILURE. PPT
CONGESTIVE CARDIAC FAILURE. PPTCONGESTIVE CARDIAC FAILURE. PPT
CONGESTIVE CARDIAC FAILURE. PPTChandrakant More
 
Hypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakamHypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakamThilakam Dhanya
 
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTION
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTIONCAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTION
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTIONPraveen Nagula
 
Risk Factors of Hypertension
Risk Factors of HypertensionRisk Factors of Hypertension
Risk Factors of HypertensionNeyaz Ahmad
 
case study on Unstable angina
case study on Unstable anginacase study on Unstable angina
case study on Unstable anginavasamviharika
 
Case presentation heart failure
Case presentation heart failureCase presentation heart failure
Case presentation heart failure政諺 郭
 
Ppt on hypertension
Ppt on hypertensionPpt on hypertension
Ppt on hypertensionpawan kumar
 
Hypertension power point
Hypertension power pointHypertension power point
Hypertension power pointkreid204
 
hypertension and diabetes - risk factors for Myocardial infarction
hypertension and diabetes - risk factors for Myocardial infarctionhypertension and diabetes - risk factors for Myocardial infarction
hypertension and diabetes - risk factors for Myocardial infarctionadithya2115
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7semiologia
 
Case triple vessel disease
Case triple vessel diseaseCase triple vessel disease
Case triple vessel diseaseDipesh Tamrakar
 

Mais procurados (20)

CHF Case Study
CHF Case StudyCHF Case Study
CHF Case Study
 
CONGESTIVE CARDIAC FAILURE. PPT
CONGESTIVE CARDIAC FAILURE. PPTCONGESTIVE CARDIAC FAILURE. PPT
CONGESTIVE CARDIAC FAILURE. PPT
 
case study presentation
case study presentationcase study presentation
case study presentation
 
CORONARY ARTERY DISEASE WITH HYPERTENSION
CORONARY ARTERY DISEASE WITH HYPERTENSIONCORONARY ARTERY DISEASE WITH HYPERTENSION
CORONARY ARTERY DISEASE WITH HYPERTENSION
 
Exercise and hypertension
Exercise and hypertensionExercise and hypertension
Exercise and hypertension
 
Hypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakamHypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakam
 
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTION
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTIONCAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTION
CAD -RISK FACTOR MODIFICATION AND PRIMARY PREVENTION
 
Hypertension
HypertensionHypertension
Hypertension
 
Risk Factors of Hypertension
Risk Factors of HypertensionRisk Factors of Hypertension
Risk Factors of Hypertension
 
case study on Unstable angina
case study on Unstable anginacase study on Unstable angina
case study on Unstable angina
 
Case presentation heart failure
Case presentation heart failureCase presentation heart failure
Case presentation heart failure
 
Ppt on hypertension
Ppt on hypertensionPpt on hypertension
Ppt on hypertension
 
Htn in ckd tarek
Htn in ckd tarekHtn in ckd tarek
Htn in ckd tarek
 
Hypertension
HypertensionHypertension
Hypertension
 
Coronary artery disease
Coronary  artery diseaseCoronary  artery disease
Coronary artery disease
 
Hypertension power point
Hypertension power pointHypertension power point
Hypertension power point
 
hypertension and diabetes - risk factors for Myocardial infarction
hypertension and diabetes - risk factors for Myocardial infarctionhypertension and diabetes - risk factors for Myocardial infarction
hypertension and diabetes - risk factors for Myocardial infarction
 
Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7Hipertensão Arterial - Slides da JNC7
Hipertensão Arterial - Slides da JNC7
 
Case triple vessel disease
Case triple vessel diseaseCase triple vessel disease
Case triple vessel disease
 
Hypertension
HypertensionHypertension
Hypertension
 

Destaque

Geriatric assessment
Geriatric assessmentGeriatric assessment
Geriatric assessmentNursing Path
 
Cbr Sangli Seminar
Cbr Sangli SeminarCbr Sangli Seminar
Cbr Sangli SeminarT Chirackal
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiologyGarima Gupta
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases pptUma Binoy
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failureIAU Dent
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failureFuad Farooq
 
Pathophysiology of congestive heart failure
Pathophysiology of congestive heart failurePathophysiology of congestive heart failure
Pathophysiology of congestive heart failurethunderrajesh
 

Destaque (12)

Chd Case Study
Chd Case StudyChd Case Study
Chd Case Study
 
Geriatric assessment
Geriatric assessmentGeriatric assessment
Geriatric assessment
 
The 10 Min Geriatric Assessment
The 10 Min Geriatric AssessmentThe 10 Min Geriatric Assessment
The 10 Min Geriatric Assessment
 
Cbr Sangli Seminar
Cbr Sangli SeminarCbr Sangli Seminar
Cbr Sangli Seminar
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiology
 
Geriatric care
Geriatric care  Geriatric care
Geriatric care
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases ppt
 
Heart Failure
Heart FailureHeart Failure
Heart Failure
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failure
 
Rheumatic Heart Disease
Rheumatic Heart DiseaseRheumatic Heart Disease
Rheumatic Heart Disease
 
Pathophysiology of congestive heart failure
Pathophysiology of congestive heart failurePathophysiology of congestive heart failure
Pathophysiology of congestive heart failure
 

Semelhante a Clinical cases for ccf

Clinical pharmacokinetic aspects of digoxin
Clinical pharmacokinetic aspects of digoxinClinical pharmacokinetic aspects of digoxin
Clinical pharmacokinetic aspects of digoxinJayDavariya1
 
Tdm of cardiovascual drugs
Tdm of cardiovascual drugsTdm of cardiovascual drugs
Tdm of cardiovascual drugsSenthilraj93
 
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASES
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASESTDM OF DRUGS USED IN CARDIOVASCULAR DISEASES
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASESHarekrishna Roy
 
Pulse therapy in dermatology.various pulse, their indication and adverse effe...
Pulse therapy in dermatology.various pulse, their indication and adverse effe...Pulse therapy in dermatology.various pulse, their indication and adverse effe...
Pulse therapy in dermatology.various pulse, their indication and adverse effe...drkishormeherkm
 
Therapeutic drug monitoring of cardiovascular drugs
Therapeutic drug monitoring of cardiovascular drugsTherapeutic drug monitoring of cardiovascular drugs
Therapeutic drug monitoring of cardiovascular drugsDr. Ramesh Bhandari
 
2-210601121744.pptx
2-210601121744.pptx2-210601121744.pptx
2-210601121744.pptxShinChanYT4
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affectewajidullah9551
 
PULSE THERAPY IN DERMATOLOGY.pptx
PULSE THERAPY IN DERMATOLOGY.pptxPULSE THERAPY IN DERMATOLOGY.pptx
PULSE THERAPY IN DERMATOLOGY.pptxPdiangtyGiriMawlong
 
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDS
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDSPREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDS
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDSDr Daulatram Dhaked
 
case presentation: generalized edema
case presentation: generalized edemacase presentation: generalized edema
case presentation: generalized edemaFatima Siddiqui
 
diabetic incipidus.pptx
diabetic incipidus.pptxdiabetic incipidus.pptx
diabetic incipidus.pptxMonika Puri
 
TDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesTDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesDr. Ramesh Bhandari
 
diabetic incipidus.pptx
diabetic incipidus.pptxdiabetic incipidus.pptx
diabetic incipidus.pptxMonika Puri
 
Therapeutic drug monitoring of cardiovascular agents
Therapeutic drug monitoring of cardiovascular agentsTherapeutic drug monitoring of cardiovascular agents
Therapeutic drug monitoring of cardiovascular agentsranjith lucky
 
Steroids in oral and maxillofacial surgery
Steroids in oral and maxillofacial surgerySteroids in oral and maxillofacial surgery
Steroids in oral and maxillofacial surgeryPrathiba Senthilkumar
 
Digitalis toxicity.pptx
Digitalis toxicity.pptxDigitalis toxicity.pptx
Digitalis toxicity.pptxHermonhaile2
 

Semelhante a Clinical cases for ccf (20)

Clinical pharmacokinetic aspects of digoxin
Clinical pharmacokinetic aspects of digoxinClinical pharmacokinetic aspects of digoxin
Clinical pharmacokinetic aspects of digoxin
 
Tdm of cardiovascual drugs
Tdm of cardiovascual drugsTdm of cardiovascual drugs
Tdm of cardiovascual drugs
 
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASES
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASESTDM OF DRUGS USED IN CARDIOVASCULAR DISEASES
TDM OF DRUGS USED IN CARDIOVASCULAR DISEASES
 
Digoxin
DigoxinDigoxin
Digoxin
 
Pulse therapy in dermatology.various pulse, their indication and adverse effe...
Pulse therapy in dermatology.various pulse, their indication and adverse effe...Pulse therapy in dermatology.various pulse, their indication and adverse effe...
Pulse therapy in dermatology.various pulse, their indication and adverse effe...
 
Corticosteroid
CorticosteroidCorticosteroid
Corticosteroid
 
Therapeutic drug monitoring of cardiovascular drugs
Therapeutic drug monitoring of cardiovascular drugsTherapeutic drug monitoring of cardiovascular drugs
Therapeutic drug monitoring of cardiovascular drugs
 
2-210601121744.pptx
2-210601121744.pptx2-210601121744.pptx
2-210601121744.pptx
 
Digoxin
DigoxinDigoxin
Digoxin
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecte
 
Cardiotonics
CardiotonicsCardiotonics
Cardiotonics
 
PULSE THERAPY IN DERMATOLOGY.pptx
PULSE THERAPY IN DERMATOLOGY.pptxPULSE THERAPY IN DERMATOLOGY.pptx
PULSE THERAPY IN DERMATOLOGY.pptx
 
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDS
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDSPREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDS
PREVENTION & MANAGEMENT OF SIDE EFFECTS OF SYSTEMIC STEROIDS
 
case presentation: generalized edema
case presentation: generalized edemacase presentation: generalized edema
case presentation: generalized edema
 
diabetic incipidus.pptx
diabetic incipidus.pptxdiabetic incipidus.pptx
diabetic incipidus.pptx
 
TDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesTDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseases
 
diabetic incipidus.pptx
diabetic incipidus.pptxdiabetic incipidus.pptx
diabetic incipidus.pptx
 
Therapeutic drug monitoring of cardiovascular agents
Therapeutic drug monitoring of cardiovascular agentsTherapeutic drug monitoring of cardiovascular agents
Therapeutic drug monitoring of cardiovascular agents
 
Steroids in oral and maxillofacial surgery
Steroids in oral and maxillofacial surgerySteroids in oral and maxillofacial surgery
Steroids in oral and maxillofacial surgery
 
Digitalis toxicity.pptx
Digitalis toxicity.pptxDigitalis toxicity.pptx
Digitalis toxicity.pptx
 

Mais de Muhammad Saim

Mais de Muhammad Saim (20)

Mc
McMc
Mc
 
Kub guide without tos
Kub guide without tosKub guide without tos
Kub guide without tos
 
Asthma copd
Asthma copdAsthma copd
Asthma copd
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Chronic stable angina
Chronic stable anginaChronic stable angina
Chronic stable angina
 
Clinical cases for ccf
Clinical cases for ccfClinical cases for ccf
Clinical cases for ccf
 
Dr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugsDr fahad anti arrythmic drugs
Dr fahad anti arrythmic drugs
 
Hypertension
HypertensionHypertension
Hypertension
 
2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranes2003 cvs shifa permeation through biological membranes
2003 cvs shifa permeation through biological membranes
 
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
Clinical pharmaco kinetics 1 bioavailability, 1st pass, renal clearance 2011
 
Arrythmia
ArrythmiaArrythmia
Arrythmia
 
Cvs
CvsCvs
Cvs
 
Retina and visual tract
Retina and visual tractRetina and visual tract
Retina and visual tract
 
Orbit
OrbitOrbit
Orbit
 
Lids,lacrimation
Lids,lacrimationLids,lacrimation
Lids,lacrimation
 
Cranial nerves iii, iv,vi
Cranial nerves iii, iv,viCranial nerves iii, iv,vi
Cranial nerves iii, iv,vi
 
Eye layers 1
Eye layers 1Eye layers 1
Eye layers 1
 
Refractive errors
Refractive errorsRefractive errors
Refractive errors
 
Limbic system
Limbic systemLimbic system
Limbic system
 

Último

SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...fonyou31
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDThiyagu K
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
9548086042 for call girls in Indira Nagar with room service
9548086042  for call girls in Indira Nagar  with room service9548086042  for call girls in Indira Nagar  with room service
9548086042 for call girls in Indira Nagar with room servicediscovermytutordmt
 

Último (20)

Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
9548086042 for call girls in Indira Nagar with room service
9548086042  for call girls in Indira Nagar  with room service9548086042  for call girls in Indira Nagar  with room service
9548086042 for call girls in Indira Nagar with room service
 

Clinical cases for ccf

  • 1. Clinical Cases for CCF Prof. Dr. Talat Ahmed
  • 2. Case Scenario for Clinical pharmacokinetics • A 64 yrs old male had heart failure was put on digoxin therapy in tablet form, formulated by XY pharmaceutical. Initially he was given 0.5 mg 8 hourly for three days followed by 0.125 mg/day. Simultaneously he was suffering from severe cough, fever and malaise, the physician after thorough investigations diagnosed as a case of lower respiratory tract infection and prescribed 100mg/d doxycycline initially for one week which was further extended to 10 days. The patient suffered from diarrhea, doxycycline was discontinued, a course of metronidazole was given and patient got cured. • After few days patient complaint of fatigue, palpitations and dyspnea. The dose of digoxin was increased to 0.25mg/ day and he felt better. • After several years he was diagnosed for chronic renal failure, blood urea and creatinine is raised. He developed heart sinking and palpitation. ECG showed pulses bigeminy. Serum digoxin was 2.8ng/ml. Digoxin therapy was stopped for three days. KCl was administered for few days The plasma level was now 1ng/ml and the dose of digoxin was adjusted to 0.125mg digoxin/day.
  • 3. Case Scenario for Clinical pharmacokinetics 1. What is form? 2. Why patient was asked to take the digoxin formulated by XY pharmaceutical only? 3. Why he suffered from diarrhea? 4. Why he was given high doses of digoxin initially? 5. Why the patient complaint of fatigue, palpitations and dyspnea. 6. Why the physician had to increase the dose of digoxin? 7. Therapeutic blood monitoring is required, at which time you will take blood sample? 8. Plasma concentration is found to be 0.35 ng/ml. How will you calculate the new dose?
  • 4. 8. What is the first symptom of digoxin toxicity leading to diagnosis? 9. Why patient developed cardiac toxicity? 10. Enumerate the formulas applied for Estimation of GFR & Creatinin clearance 11.What is the normal range of serum digoxin level? 12. After increasing the dose to 0.25 mg/day how long it took to improve the patients condition and was stabilized? 13. What is the mechanism of development of pulses bigeminy? 14. What will be effect of chronic renal failure on plasma half life of digoxin? 15. Later, on reducing the dose from 0.25 to 0.125 mg, how long will it take to reach Css?
  • 5. Clinical Evidences Doxycycline • Antibiotics might increase digoxin absorption by inactivating intestinal bacteria • John R Horn, Pharmacy times 2004 Azole Derivatives • Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Cardiac Glycosides. (UpToDate)
  • 6. Doxycycline • Unlike many tetracyclines, doxycycline does not appear to accumulate in patients with impaired renal function, and aggravation of impairment may be less likely. Similarly, there is also no evidence that doxycycline causes severe hepatitis (BMJ)
  • 7. Metronidazole • DOSING: RENAL IMPAIRMENT • To reduce possible accumulation in patients receiving multiple doses, consider reduction to 50% of dose or every 12 hours; Note: Dosage reduction is unnecessary in short courses of therapy. Some references do not recommend reduction at any level of renal impairment (Lamp, 1999). • DOSING: HEPATIC IMPAIRMENT — Unchanged in mild liver disease; reduce dosage in severe liver disease.
  • 8. 4-variable MDRD," (Modification of Diet in Renal Disease Study Group) serum creatinine, age race, & Gender. CKD-EPI including urinary albumin
  • 9. NSR=normal sinus rhythem PVB= premature ventricular beat
  • 10. Therapeutic Dose Toxic dose